Telix Pharmaceuticals Limited (TLPPF)
USD 18.99
(3.77%)
USD 18.99
(3.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 298.55 Million AUD | 38.97% |
| 2022 | 189.44 Million AUD | 87.29% |
| 2021 | 101.15 Million AUD | 92.88% |
| 2020 | 52.44 Million AUD | 27.29% |
| 2019 | 41.19 Million AUD | 47.93% |
| 2018 | 27.84 Million AUD | 326.93% |
| 2017 | 6.52 Million AUD | 21643.75% |
| 2016 | 30 Thousand AUD | -74.14% |
| 2015 | 116 Thousand AUD | 0.0% |
| 2000 | -994 Thousand AUD | -71.97% |
| 1999 | -578 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 84.51 Million AUD | -72.97% |
| 2024 Q2 | 96.85 Million AUD | 99.83% |
| 2023 FY | 263.27 Million AUD | 38.97% |
| 2023 Q3 | 79.04 Million AUD | 33.13% |
| 2023 Q2 | 59.37 Million AUD | -13.2% |
| 2023 Q4 | 203.9 Million AUD | 157.96% |
| 2023 Q1 | 68.4 Million AUD | 25.29% |
| 2022 Q3 | 54.57 Million AUD | 13.89% |
| 2022 Q4 | 54.59 Million AUD | 0.03% |
| 2022 FY | 189.44 Million AUD | 87.29% |
| 2022 Q1 | 42.03 Million AUD | 35.35% |
| 2022 Q2 | 47.92 Million AUD | 14.0% |
| 2021 Q4 | 31.05 Million AUD | 21.94% |
| 2021 Q3 | 25.47 Million AUD | 24.71% |
| 2021 FY | 101.15 Million AUD | 92.88% |
| 2021 Q2 | 20.42 Million AUD | 18.71% |
| 2021 Q1 | 17.2 Million AUD | -17.65% |
| 2020 Q3 | 15.55 Million AUD | 35.45% |
| 2020 FY | 52.44 Million AUD | 27.29% |
| 2020 Q4 | 20.89 Million AUD | 34.3% |
| 2020 Q2 | 11.48 Million AUD | 15.5% |
| 2020 Q1 | 9.94 Million AUD | -45.86% |
| 2019 Q3 | 9.66 Million AUD | -3.44% |
| 2019 FY | 41.19 Million AUD | 47.93% |
| 2019 Q4 | 18.36 Million AUD | 89.94% |
| 2019 Q1 | 6.35 Million AUD | 16.75% |
| 2019 Q2 | 10.01 Million AUD | 57.62% |
| 2018 Q3 | 5.44 Million AUD | 103.77% |
| 2018 Q4 | 5.44 Million AUD | 0.0% |
| 2018 FY | 27.84 Million AUD | 326.93% |
| 2018 Q1 | 2.67 Million AUD | 10.82% |
| 2018 Q2 | 2.67 Million AUD | -0.0% |
| 2017 FY | 6.52 Million AUD | 21643.75% |
| 2017 Q4 | 2.4 Million AUD | 0.0% |
| 2017 Q3 | 2.4 Million AUD | 202.85% |
| 2017 Q1 | 795.67 Thousand AUD | 0.0% |
| 2017 Q2 | 795.67 Thousand AUD | 0.0% |
| 2016 FY | 30 Thousand AUD | -74.14% |
| 2015 FY | 116 Thousand AUD | 0.0% |
| 2000 FY | -994 Thousand AUD | -71.97% |
| 1999 FY | -578 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 29.55 Million USD | -910.219% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -5821.21% |
| CSL Limited | 3.44 Billion USD | 91.344% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -701.354% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -32227.75% |
| BioStem Technologies, Inc. | 22.97 Million USD | -1199.467% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -2647.308% |
| Qrons Inc. | 643.67 Thousand USD | -46281.959% |
| Nascent Biotech, Inc. | 2.22 Million USD | -13288.619% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -419.76% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -4344.021% |
| Skye Bioscience, Inc. | 13.54 Million USD | -2103.719% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -71756.821% |
| Rebus Holdings, Inc. | 664 Thousand USD | -44862.349% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -1764.744% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -22256.078% |
| Genscript Biotech Corporation | 825.34 Million USD | 63.827% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -76536.565% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -244.011% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -5970.665% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -113969.676% |
| SQZ Biotechnologies Company | 85.61 Million USD | -248.696% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -10137.515% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -19778.168% |
| Mesoblast Limited | 5.9 Million USD | -4958.455% |
| Marizyme, Inc. | 19.23 Million USD | -1451.729% |
| Genus plc | 147.7 Million USD | -102.133% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -3300.638% |
| Pharming Group N.V. | 225.49 Million USD | -32.4% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -14472.62% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -22154.192% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -3480.165% |
| ContraFect Corporation | 56.88 Million USD | -424.794% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -6671.881% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -20089.322% |
| IMV Inc. | 37.7 Million USD | -691.716% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -10599.348% |
| MultiCell Technologies, Inc. | 567.42 USD | -52615246.657% |
| ONE Bio Corp. | 6.44 Million USD | -4533.07% |
| Accustem Sciences Inc. | 3.74 Million USD | -7868.943% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -247.373% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -56022.43% |
| Q BioMed Inc. | 3.43 Million USD | -8587.295% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -1107.971% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -11262.417% |
| Biomind Labs Inc. | 994.18 Thousand USD | -29929.713% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -200.563% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -16866.172% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -15913.452% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1194300.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -16168.913% |
| GB Sciences, Inc. | 1.42 Million USD | -20917.114% |
| Alpha Cognition Inc. | 9.7 Million USD | -2976.059% |
| HST Global, Inc. | 140.9 Thousand USD | -211777.338% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -26439.901% |
| Halberd Corporation | 74.84 Thousand USD | -398807.031% |
| Enzolytics Inc. | 2.17 Million USD | -13598.052% |
| Agentix Corp. | 1.37 Million USD | -21664.075% |
| Resverlogix Corp. | 12.71 Million USD | -2248.568% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -8077.868% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 80.532% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -28496.743% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -12314.062% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -18803.286% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -8668.042% |
| AVAX Technologies, Inc. | 7.31 Million USD | -3983.984% |
| Zenith Capital Corp. | 8.94 Million USD | -3238.365% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -1713636.295% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -12059.326% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -173972.498% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -15442.145% |
| Kadimastem Ltd | 2.41 Million USD | -12287.391% |
| Helix BioMedix, Inc. | 1.97 Million USD | -15039.191% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -164403.953% |
| LadRx Corporation | 3.81 Million USD | -7732.276% |
| Cell Source, Inc. | 4.32 Million USD | -6802.338% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -32227.75% |
| NovAccess Global Inc. | 2.46 Million USD | -12002.916% |
| Affymax, Inc. | 39.38 Million USD | -658.01% |
| Itoco Inc. | 919.14 Thousand USD | -32381.344% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -6943.908% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -26580.071% |
| Mobile Lads Corp. | 554.54 Thousand USD | -53736.832% |
| CytoDyn Inc. | 18.05 Million USD | -1553.284% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -1186081.414% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -135556.449% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -20927.728% |
| SYBLEU INC | 160.87 Thousand USD | -185477.712% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -16337.082% |
| International Stem Cell Corporation | 5.27 Million USD | -5564.011% |
| Bioxytran, Inc. | 3.82 Million USD | -7715.144% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -567032.708% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -1467480.986% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -723.223% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -18351.792% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -40472.955% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -9496.593% |
| Neutra Corp. | 243.82 Thousand USD | -122346.385% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1610.202% |
| PureTech Health plc | 144.59 Million USD | -106.47% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -1357.06% |
| IXICO plc | 4.7 Million USD | -6242.681% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -3293.771% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -153.55% |
| CSL Limited | 3.89 Billion USD | 92.331% |
| Cellectis S.A. | 97.32 Million USD | -206.771% |